PDF: Update on Drugs & Devices: November-December 2024

PDF Download: Update on Ruxolitinib phosphate cream 1.5% (Opzelura®), Roflumilast foam 0.3% (Zoryve®), Clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% fixed-dose topical gel (Cabtreo™), Lebrikizumab-lbkz (Ebglyss™ SC injection), Ustekinumab-srlf (Imuldosa™ SC/IV injection), Ustekinumab-aauz (Otulfi™ SC/IV injection), Ustekinumab biosimilar (Pyzchiva™ SC/IV injection).
Read online:
Update on Drugs & Devices: November-December 2024